Results 231 to 240 of about 245,088 (289)

Immunologic Profiling Suggests an Association Between Treg Cell Dysfunction and Pain in Knee Osteoarthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Pain is the hallmark symptom of osteoarthritis (OA), and its biologic drivers remain poorly understood. Although the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular Treg cells, is not well understood.
Marie Binvignat   +26 more
wiley   +1 more source

Hematological complications in solid organ transplant recipients with telomere biology disorders: a narrative review. [PDF]

open access: yesFront Immunol
Carlier FM   +6 more
europepmc   +1 more source

Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition

open access: yesArthritis &Rheumatology, EarlyView.
Objective Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Because mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong   +13 more
wiley   +1 more source

Intestinal and multiple organ transplantation [PDF]

open access: yes, 2000
Abu-Elmagd, K   +6 more
core  

CD14 plays a critical role in pain and inflammation across multiple models of post‐traumatic osteoarthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives We employed global genetic deletion of CD14 and intra‐articular CD14 blockade across multiple murine OA models that vary in severity of pathology and rate of progression, to test the hypothesis that CD14 inhibition attenuates synovial inflammation and associated pain during disease progression.
Kevin G. Burt   +18 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy